http://bmj.com/cgi/content/full/323/7323/1208/a

 

BMJ 2001;323:1208 ( 24 November )

News extra

Communicable disease network strengthened against bioterrorism

Rory Watson Brussels

European health ministers are planning to strengthen and extend the existing European Union's communicable diseases network so that it can be used in the event of bioterrorist attacks.

The network already links a number of national surveillance institutes, and EU legislation lists the communicable diseases that need to be placed under continent-wide surveillance—such as tuberculosis, measles, influenza, AIDS, and hepatitis C.

The London based Communicable Disease Surveillance Centre, for example, is acting as the hub of the operation to track developments linked to legionellosis and salmonellosis infection with Escherichia coli O157, and the Institut de Veille Sanitaire in Paris is performing the same role for tuberculosis and HIV and AIDS.

Similar networks are also in place to monitor any outbreaks of flu, viral haemorrhagic fevers, antimicrobial resistance, and nosocomial infections.

But others, covering hepatitis C, meningococcal disease, measles, brucellosis, and rabies and involving institutes in Stockholm, Berlin, Rome, Athens, and London, are only in their pilot phase. At their Brussels meeting in mid-November, EU health ministers agreed that efforts should be made to make these networks fully operational.

They also decided that the network could be developed to keep national authorities informed of any potential bioterrorist risks and to deploy joint investigation teams. It will now be used to disseminate information on Europe’s supplies of serums, vaccines, and antibiotics and on the ability of its laboratories to produce the quantities that might be needed in the event of an attack.

In addition to its surveillance role, the network includes an early warning and response system to alert public health authorities of outbreaks of diseases that could quickly spread across national borders. This is designed to enable early consultation between experts on the risk management required to protect populations that could be in danger. The European Commission believes that the network is beginning to prove its worth and points to its use during recent outbreaks of paratyphoid fever in Turkey, legionnaires' disease in Belgium, and Lassa fever in Germany.

ALL INFORMATION, DATA, AND MATERIAL CONTAINED, PRESENTED, OR PROVIDED HERE IS FOR GENERAL INFORMATION PURPOSES ONLY AND IS NOT TO BE CONSTRUED AS REFLECTING THE KNOWLEDGE OR OPINIONS OF THE PUBLISHER, AND IS NOT TO BE CONSTRUED OR INTENDED AS PROVIDING MEDICAL OR LEGAL ADVICE.  THE DECISION WHETHER OR NOT TO VACCINATE IS AN IMPORTANT AND COMPLEX ISSUE AND SHOULD BE MADE BY YOU, AND YOU ALONE, IN CONSULTATION WITH YOUR HEALTH CARE PROVIDER.